# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, re...
Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a sign...
PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | ...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...
Initial Phase 1 data expected by year-end 2024